Company CVAbout Procter & Gamble Health Ltd 
Procter & Gamble Health Ltd
Mid Cap
Pharmaceuticals & Drugs
Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in year 1967. The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002. Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
Company Coordinates
Company Details
Godrej One 8th Floor, Projshanagar Vikhroli (East) Mumbai Maharashtra : 400079
Registrar Details
Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 16.60 Cr
Number of Shares
1.66 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
09-Oct-2009
1.66
16.60
-50
10
Buy Back of Shares
09-Oct-2009
1.66
16.60
-50
10
Buy Back of Shares
01-Oct-2009
1.66
16.60
-50
10
Buy Back of Shares
01-Oct-2009
1.66
16.60
-50
10
Buy Back of Shares
24-Sep-2009
1.66
16.60
-1494
10
Buy Back of Shares
24-Sep-2009
1.66
16.60
-1494
10
Buy Back of Shares
16-Sep-2009
1.66
16.63
-80000
10
Buy Back of Shares
16-Sep-2009
1.66
16.60
-33044
10
Buy Back of Shares
16-Sep-2009
1.66
16.63
-80000
10
Buy Back of Shares
16-Sep-2009
1.66
16.60
-33044
10
Buy Back of Shares
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 13 Schemes (10.64%)
FIIs
Held by 123 FIIs (7.02%)
Promoter with highest holding
Procter And Gamble Overseas India B.v. (51.82%)
Highest Public shareholder
Nippon Life India Trustee Ltd-a/c Nippon India Sma (4.1%)
Individual Investors Holdings
21.34%
Board of Directors
Management
Designation
Remuneration
S N Talwar
Chairman & Independent Directo
17.75 lacs
Rani A Jadhav
Independent Director
15.55 lacs
Milind Thatte
Managing Director
3.87 cr
Amit Gupta
Director (Finance) & CFO
1.87 cr
Aalok Agrawal
Director
0
Zeal Shah
Company Sec. & Compli. Officer
12.0 lacs
Elizabeth Desmond
Director
0
S Madhavan
Independent Director
8.9 lacs
Lokesh Chandak
Executive Director
0
Seema Sambasivan
Non Executive Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical Products
479.32
56.46%
Traded Goods
338.87
39.91%
Other Operating Income
30.80
3.63%
Pharmaceutical Products
Pharmaceutical Products
Traded Goods
Traded Goods
Other Operating Income
Other Operating Income
Stock DNARevenue and Profits:
Net Sales:
310 Cr
(Quarterly Results - Dec 2024)
Net Profit:
91 Cr
Pharmaceuticals & Drugs
INR 8,670 Cr (Mid Cap)
34.00
33
2.70%
-0.43
41.18%
14.11
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
